News
European Commission expands denosumab indication
Following the FDA’s lead, the European Commission approves denosumab for prevention of skeletal-related events.
News
MRD may indicate relapse risk in AML
The presence of molecular minimal residual disease, despite complete remission, could be an independent predictor of future relapse risk.
Video
VIDEO: How to prepare PTCL patients for transplant
LA JOLLA, CALIF. – Dr. Steven Horwitz says the key to preparing patients for transplant is “good remission.”
News
FDA approves nilotinib for children with CML
The decision expands the drug’s indication to include first- and second-line use in children.
News
FDA approves new option in Hodgkin lymphoma treatment
The approval is based on results from the ECHELON-1 trial in previously untreated patients with stage III or IV classical Hodgkin lymphoma.
News
Time to rethink MCL treatment, trial design
Dr. Leonid Yavorkovsky of Kaiser Permanente San Jose Medical Center questions the traditional approach to treatment of class mantle cell lymphoma...
News
Consider steroid-induced hypertension when treating pediatric ALL
Infants and children with secondary diabetes mellitus were among those most likely to develop steroid-induced hypertension.
News
Hemophilia A treatment gains approval in Europe
Emicizumab is now approved in Europe and the United States for routine prophylaxis of bleeding episodes in people with factor VIII inhibitors.
News
FDA approves tests to screen for tickborne parasite in blood supply
The two new tests will screen whole blood and plasma samples.
News
Phase 2 study tests low-dose maintenance therapy for ALL
The trial is expected to enroll 40 adult ALL patients in complete remission with positive minimal residual disease.
News
Gene therapy for hemophilia A gets fast-track review
The FDA has granted breakthrough therapy designation to a gene therapy product aimed at hemophilia A.
News
FDA grants priority review for AML drug
The FDA is expected to make a decision in August 2018.
News
Three-drug combo delivers PFS for myeloma in OPTIMISMM trial
Celgene announced the phase 3 trial results, which investigators intend to present at future meetings.
News
Hemophilia A drug heads toward approval in Europe
The drug was approved by the U.S. Food and Drug Administration in November 2017.
News
Real-world study makes case for continuous treatment in multiple myeloma
The study evaluated more than 600 adults with newly diagnosed multiple myeloma who relapsed.